The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On May 22, 2017, Amgen disclosed that its osteoporosis medicine Evenity raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by the Company, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine.
On this news, Amgen's share price has fallen as much as $3.42 or 2.20%, during intraday trading on May 22, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:Robert S. WilloughbyPomerantz [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amgen-inc--amgn-300461711.html
SOURCE Pomerantz LLP
